OSE-279抗PD-1单抗晚期实体瘤I期剂量递增研究
OSE-279为高亲和力人源化抗PD-1双价单克隆抗体,在晚期实体瘤患者中开展I期剂量递增研究,评估安全性、药代动力学、药效动力学及抗肿瘤活性。
要点
- OSE-279单药在晚期实体瘤中安全性良好,确立300 mg q3w与600 mg q6w两个II期推荐剂量。
- 常见≥10%相关TEAE包括腹泻、口干、瘙痒、寒战、乏力、头痛、味觉障碍及甲状腺功能亢进。
- PK呈线性剂量比例,所有测试剂量平均受体占有率维持80%以上。
核心结论
- OSE-279单药耐受性良好,在晚期实体瘤患者中产生持久缓解。
研究设计与样本
- 中位年龄61.5岁(范围3-81),女性占50%,既往转移线中位数2线(范围1-6)。
- 最常见瘤种为软组织肉瘤(n=4)和肛管鳞状细胞癌(n=3)。
主要发现
- 最常见(≥10%)相关TEAE为腹泻、口干、瘙痒、寒战、乏力、头痛、味觉障碍及甲状腺功能亢进。
- OSE-279药代动力学呈线性剂量比例,所有测试剂量平均受体占有率维持80%以上。
- 300 mg q3w组1例CR,600 mg q6w组4例PR,7例SD,缓解持续时间6.8至18.4个月。
关键数值与推荐
- 确立两个II期推荐剂量:300 mg q3w和600 mg q6w。
- 所有测试剂量平均受体占有率维持80%以上。
临床怎么用
- OSE-279单药可用于晚期实体瘤,推荐II期剂量为300 mg q3w或600 mg q6w。
- 试验正在继续,探索OSE-279联合治疗性癌症疫苗OSE2101用于HLA-A2阳性且PD-L1≥50%的NSCLC一线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: OSE-279 is a high affinity humanized monoclonal bivalent antibody against PD-1 with potent antitumor activity in vivo in syngeneic non-clinical models. METHODS: This phase I study assessed the safety, pharmacokinetics, pharmacodynamics and antitumor activity of OSE-279 in advanced solid tumours. RESULTS: Twenty patients received OSE-279 intravenously at 100 mg q3w (n = 2), 300 mg q3w (n = 7) and 600 mg q6w (n = 11). Median age was 61.5 (range 3-81) years, 50% were female, median number of prior metastatic lines was 2 (range 1-6). Most frequent tumour types were soft tissue sarcoma (n = 4) and anal squamous cell carcinoma (n = 3). OSE-279 monotherapy was safe. Two recommended phase 2 doses were established: 300 mg q3w and 600 mg q6w. The most common (≥10%) related TEAEs were diarrhoea, dry mouth, pruritus, chills, fatigue, headache, dysgeusia and hyperthyroidism. OSE-279 PK exhibited linear dose proportionality and mean receptor occupancy was maintained above 80% in all tested doses. There were 1 CR at 300 mg q3w, 4 PRs at 600 mg q6w and 7 SD with response duration ranging from 6.8 to 18.4 months. CONCLUSION: OSE-279 monotherapy was well tolerated with durable responses in patients with advanced solid tumours. The trial is continuing with OSE-279 combined with OSE2101, a therapeutic cancer vaccine in 1st line HLA-A2 positive PD-L1 ≥ 50% NSCLC. CLINICAL TRIAL REGISTRATION (NCT NUMBER: NCT05751798).
引用
- Robert M, Kotecki N, Gomez-Roca C, et al. A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours. Eur J Cancer. 2026. PMID: 42034003. doi:10.1016/j.ejca.2026.116729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。